8-KMaterial AgreementsRegulation FDExhibits & Filings

STRYKER CORP 8-K Report, Material Agreement (Jan 7, 2025)

Filed January 7, 2025For Securities:SYK

Summary

Stryker Corporation (SYK) has announced a significant strategic move through an Agreement and Plan of Merger with Inari Medical, Inc., filed on January 6, 2025. The transaction involves Stryker initiating a tender offer to acquire all outstanding shares of Inari Medical for $80.00 per share in cash. This acquisition aims to expand Stryker's presence in the medical device market, likely in areas related to Inari's specialization in minimally invasive treatments for venous and arterial diseases. The deal is subject to customary closing conditions, including a majority tender of Inari's shares and regulatory approvals, such as the Hart-Scott-Rodino Antitrust Improvements Act. The tender offer is expected to commence shortly and will remain open for a minimum of 20 business days. Following a successful tender offer, Stryker intends to complete the acquisition through a merger. Investors should note the 'no-shop' clause for Inari, though exceptions exist for superior proposals, and a termination fee of $163 million if the deal is not completed under specific circumstances, such as Inari accepting a superior offer or Stryker terminating due to a change in Inari's recommendation.

Key Highlights

  • 1Stryker enters into a definitive agreement to acquire Inari Medical for $80.00 per share in cash.
  • 2The acquisition will be conducted via a tender offer followed by a merger.
  • 3The total transaction value implies a significant premium for Inari shareholders.
  • 4Key closing conditions include a majority tender of Inari shares and regulatory approvals (e.g., HSR Act).
  • 5Inari is subject to customary 'no-shop' provisions, with provisions for evaluating superior proposals.
  • 6A termination fee of $163 million is stipulated under certain circumstances.
  • 7The tender offer is expected to commence soon and will be subject to standard offer terms and conditions.

Frequently Asked Questions

Stryker is offering $80.00 per share in cash for all outstanding shares of Inari Medical common stock.

The acquisition is contingent upon several conditions, including a minimum tender of a majority of Inari's outstanding shares, expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and the absence of any governmental prohibition on the transaction.

The tender offer has not yet commenced. Once commenced, it will remain open for a minimum of 20 business days. Stryker may be obligated to extend the offer under certain conditions, but not beyond specific end dates outlined in the merger agreement.

Inari may be required to pay Stryker a termination fee of $163 million under specific circumstances, such as if Inari terminates the agreement to accept a superior acquisition proposal or if Stryker terminates due to Inari's board changing its recommendation to shareholders.